Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Fokus Mining Intersects 10 Metres Grading 10.06 G/T At The Galloway Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Erasca Inc ERAS

Healthcare Biotechnology
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline including 12 disclosed modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ERAS)

Erasca Announces $45 Million Oversubscribed Private Placement Financing

GlobeNewswire March 27, 2024

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

GlobeNewswire March 27, 2024

Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

GlobeNewswire February 14, 2024

Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire February 1, 2024

Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

GlobeNewswire December 11, 2023

Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

GlobeNewswire November 28, 2023

Erasca Reports Third Quarter 2023 Financial Results and Business Updates

GlobeNewswire November 9, 2023

Erasca to Present at Upcoming Investor Conferences in November

GlobeNewswire November 8, 2023
View More News ››

Opinion & Analysis (NDAQ:ERAS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ERAS)

Be the first to post on this bullboard.

Xcyte Digital Corp.

Xcyte Digital Corp.

Xcyte Digital is a virtual event company focused on simplifying the event hosting industry and expanding event hosting ...
View More »